Jump to Main Contents

Home > Organization > Fundamental Innovative Oncology Core（FIOC） > Department of Immune Medicine > Research Papers

Research Papers

Publications since 2022

  1. Hirata A, Sawai E, Henmi M, Shibasaki C, Mizoguchi Y, Narumi K, Aoki K. Imatinib mesylate exerted antitumor effect by promoting increased infiltration of effector T cells in tumor. Biol Pharm Bull 45; 34-41, 2022.
  2. Zhang M, Kiyono T, Aoki K, Goshima N, Kobayashi S, Hiranuma K, Shiraishi K, Saya H, Nakahara T. Development of an in vitro carcinogenesis model of HPV-induced cervical adenocarcinoma. Cancer Sci 113; 904-915, 2022.
  3. Furuya G, Katoh H, Atsumi S, Hashimoto I, Komura D, Hatanaka R, Senga S, Hayashi S, Akita S, Matsumura H, Miura A, Mita H, Nakakido M, Nagatoishi S, Sugiyama A, Suzuki R, Konishi H, Yamamoto A, Abe H, Hiraoka N, Aoki K, Kato Y, Ushiku T, Seto Y, Yoshimura C, Miyadera K, Tsumoto K, Ishikawa S. Identification of pH-selective Dual-specific Human Antibodies with Therapeutic Applicability Dominated through Tumor-driven Epitope Spreading. Cancer Sci 114; 48-62, 2023.
  4. Karayama M, Mizoguchi Y, Inoue Y, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Suda T, Kitano S, Aoki K, Yamada Y. An increase in peripheral blood CD86-positive plasmacytoid dendritic cells is associated with immune-related adverse events after immune checkpoint inhibitor therapy in patients with non-small cell lung cancer. Global Health Med 4: 301-308, 2022
  5. Yoshida S, Hamada Y, Narita M, Sato D, Tanaka K, Mori T, Tezuka H, Suda Y, Tamura H, Aoki K, Kuzumaki N, Narita M. Elucidation of the mechanisms underlying tumor aggravation by the activation of stress-related neurons in the paraventricular nucleus of the hypothalamus. Molecular Brain 16, Article number: 18, 2023.
  6. Aoki K, Nishito N, Motoi N, Arai Y, Hiraoka N, Shibata T, Sonobe Y, Kayukawa Y, Hashimoto E, Takahashi M, Fujii E, Nishizawa T, Fukuda H, Ohashi K, Arai K, Mizoguchi Y, Yoshida Y, Watanabe S, Yamashita M, Kitano S, Sakamoto H, Nagata Y, Mitsumori R, Ozaki K,Niida S, Kanai Y, Hirayama A, Soga T, Maruyama T, Tsukada K, Yabuki N, Shimada M, Kitazawa T, Natori O, Sawada N, Kato A, Yoshida T, Yasuda K, Mizuno H, Tsunoda H, Ochiai A. Tumor-infiltrating lymphocyte profiling defines three immune subtypes of NSCLC with distinct signaling pathways and genetic alterations. Cancer Res Commun 3: 1026–1040, 2023.
  7. Sri-iesaranusorn P, Sadahiro R, Murakami S, Wada S, Shimizu K, Aoki K, Uezono Y, Yoshida T, Matsuoka H, Ikeda K, Yoshimoto J. Data-driven subtyping of postoperative delirium using unsupervised machine learning. Front Psychiatry 14: 1205605, 2023.
  8. Mitsunaga S, Ikeda M, Imaoka H, Sasaki M, Watanabe K, Sato A, Aoki K, Ochiai A, Makikawa M, Nishidate M, Yamaguchi K, Terao K, Sawada N, Fujitomo T, Fujii E, Kato A, Tsunoda H. Fibroblast inhibition by tocilizumab enabled gemcitabine/nab-paclitaxel rechallenge for pancreatic cancer. Cancer Sci 14: 4006-4019, 2023.
  9. Ohashi K, Nishito Y, Fukuda H, Sadahiro R, Yoshida Y, Watanabe S, Motoi N, Sonobe Y, Mizuno M, Tsunoda H, Tatsumi K, Suzuki T, Ochiai A, Aoki K. Neutrophil-to-lymphocyte ratio is a prognostic marker reflecting immune condition of tumor microenvironment in squamous cell lung cancer. Sci Rep 14, Article number: 429, 2024.
  10. Sakashita M, Motoi N, Yamamoto G, Gambe E, Suzuki S, Yoshida Y, Watanabe S, Takazawa Y, Aoki K, Ochiai A, Sakashita S. Machine-based counting of mitochondria in cells using immunohistochemical staining of formalin-fixed and paraffin-embedded sections. J Cancer Res Clin Oncol 150; 172, 2024.
  11. Fukuda H, Arai K, Mizuno H, Nishito Y, Motoi N, Arai Y, Hiraoka N, Shibata T, Sonobe Y, Kayukawa Y, Hashimoto E, Takahashi M, Fujii E, Nishizawa T, Mizoguchi Y, Yoshida Y, Watanabe S, Yamashita M, Kitano S, Sakamoto H, Nagata Y, Mitsumori R, Ozaki K, Niida S, Kanai Y, Hirayama A, Soga T, Maruyama T, Tsukada K, Yabuki N, Shimada M, Kitazawa T, Natori O, Sawada N, Kato A, Yoshida T, Yasuda K, Ochiai A, Tsunoda H, Aoki K. Molecular subtypes of lung adenocarcinoma presents distinct immune tumor microenvironment. Cancer Sci 115: 1763-1777, 2024.
  12. Shoji H, Kudo-Saito C, Nagashima K, Imazeki H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Aoki K, Muro K, Boku N. Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study). J Immunother Cancer 12: e010174, 2024.
  13. Ishihara H, Fukuda H, Mizoguchi Y, Yamashita M, Aoki K, Ishiyama R, Ikeda T, Nemoto Y, Shimmura H, Hashimoto Y, Yoshida K, Hirai T, Iizuka J, Tokita D, Kondo T, Nagashima Y, Takagi T. Sex differences in treatment outcomes in patients with advanced renal cell carcinoma: A retrospective examination of immune checkpoint inhibitor efficacy and tumor infiltrating immune cell profiles. Cancer Immunol Immunother 74: 51, 2025.
  14. Arai K, Nishito Y, Mizuno H, Motoi N, Hiraoka N, Fuse M, Arai Y, Shibata T, Sonobe Y, Kayukawa Y, Maruyama T, Fukuda H, Mizoguchi Y, Aikawa Y, Yoshida Y, Watanabe S, Sakamoto H, Yamashita M, Kitano S, Nagata Y, Mitsumori R, Ozaki K, Niida S, Kanai Y, Hirayama A, Soga T, Yoshida T, Yasuda K, Ochiai A, Tsunoda H, Aoki K. EML4-ALK-rearrangement constructs a distinctive myeloid-cell-dominant immunosuppressive microenvironment in lung cancer. Cancer Immunol Res 13: 1435-1452, 2025.
  15. Sadahiro R, Ohbuchi K, Nakaya T, Manabe S, Wada S, Yamaguchi T, Sugimoto M, Shimizu K. Sato T, Esaki M, Daiko H, Yoshimoto S, Kanemitsu Y, Kawai A, Ishikawa M, Matsui Y, Aoki K, Ueno T, Matsuoka H, Uezono Y. Metabolome profiling of Yokukansan in preventing postoperative delirium in elderly cancer patients: a reverse translational study. Psychiatry Clin Neurosci Aug 5, 2025. doi: 10.1111/pcn.13875.
  16. Sadahiro R, Koyama R, Kuchiba A, Wada S, Shimizu K, Yoshida Y, Aoki K, Uezono Y, Matsuoka H, Saito E. Medical cost of postoperative delirium after highly invasive cancer resection: a prospective cohort study. Jpn J Clin Oncol 56 : 187-195, 2026.
  17. Ishihara H, Liu Y, Yamashita R, Fukuda H, Mizoguchi Y, Yamashita M, Kitano S, Aoki K, Tachibana H, Mizoguchi S, Nishimura K, Nakayama T, Nemoto Y, Yoshida K, Hirai T, Iizuka J, Nagashima Y, Ushijima T, Tokita D, Kondo T, Takagi T. Non-clear-cell renal cell carcinoma has an immune cold phenotype that impacts response to immune checkpoint inhibitors. Mol Cancer Res 2026 Jan 27. doi: 10.1158/1541-7786.MCR-25-0939.
  18. Fukuda H, Arai K, Hashimoto E, Sekine K, Arai Y, Hiraoka N, Hirata A, Yamashita M, Narumi K, Kikuchi, Sawai E, Sawada Y, Sunami A, Mizoguchi Y, Sadahiro R, Aikawa Y, Henmi Y, Shibata T, Nishito Y, Mizuno H, Nara S, Esaki M, Kitano S, Yoshida T, Ochiai A, Tsunoda H, Aoki K. MIF-CD74 axis facilitates MDSC infiltration in the tumor microenvironment of pancreatic ductal adenocarcinoma. Cancer Lett 645, 1 May, 218348, 2026.

    • Our Research Focus